Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients

Aires, 2011, New insights on the metabolism of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA, J. Hepatol., 55, 426, 10.1016/j.jhep.2010.11.031 Aiyer, 2016, Valproic acid induced hyperammonemia in a long time treated patient, Case Rep. Psychiatr., 2016 Baddour, 2018, Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management, Ment. Health Clin., 8, 73, 10.9740/mhc.2018.03.073 Brown, 2018, Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: a case series and literature review, Ment. Health Clin., 8, 148, 10.9740/mhc.2018.05.148 Chopra, 2012, Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management, Gen. Hosp. Psychiatry, 34, 290, 10.1016/j.genhosppsych.2011.12.009 Clay, 2007, Hyperammonemia in the ICU, Chest., 132, 1368, 10.1378/chest.06-2940 Hospira, Inc : Depacon (valproate sodium) for intravenous injection, USP [package insert]. McPherson, KS, Hospira, Inc. Maldonado, 2017, L-carnitine supplementation to reverse a patient undergoing chronic valproic acid treatment: a case report, J. Int. Med. Res., 45, 1268, 10.1177/0300060517703278 Mock, 2012, Levocarnitine for valproic acid-induced hyperammonemic encephalopathy, Am. J. Health-Syst. Pharm., 69, 35, 10.2146/ajhp110049 Ohtani, 1982, Carnitine deficiency and hyperammonemia associated with valproic acid therapy, J. Pediatr., 101, 782, 10.1016/S0022-3476(82)80320-X Sousa, 2013, Valproic acid-induced hyperammonemic encephalopathy – a potentially fatal adverse drug reaction, Springerplus, 2, 13, 10.1186/2193-1801-2-13 Yamamoto, 2012, Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients, Epilepsy Res., 101, 202, 10.1016/j.eplepsyres.2012.04.001